Ashvin R. Jaiswal

1.3k citations
14 papers · 914 indexed · h-index 9

Ashvin R. Jaiswal

14 papers receiving 902 citations

Peers

Ashvin R. Jaiswal
Comparison fields: 5 of 94
  • Immunology 482
  • Oncology 387
  • Cancer Research 195
  • Biomaterials 99
  • Biomedical Engineering 161
Replace Yuan‐Tong Liu with:
Yuan‐Tong Liu China
Christina Hartl United States
Ana Bocanegra Spain
Jonathan Wilhelm United States
Yoonjeong Choi South Korea
May Tun Saung United States
James W. Opzoomer United Kingdom
Xiaoli Wei China
Shengjie Chai United States
Matthew Lin United States
Ashvin R. Jaiswal relative to Yuan‐Tong Liu China Yuan‐Tong Liu's profile →
Citations per field
00.5×10×15.3×
Yuan‐Tong Liu · 1×
Citations per year

Countries citing papers authored by Ashvin R. Jaiswal

Since Specialization
Citations

This map shows the geographic impact of Ashvin R. Jaiswal's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ashvin R. Jaiswal with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ashvin R. Jaiswal more than expected).

Fields of papers citing papers by Ashvin R. Jaiswal

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ashvin R. Jaiswal. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ashvin R. Jaiswal. The network helps show where Ashvin R. Jaiswal may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Ashvin R. Jaiswal, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Ashvin R. Jaiswal Line = papers co-authored together Ashvin R. Jaiswal links everyone, so they are left out of the graph.

All Works

14 of 14 papers shown
#Work
1 20227
2 202043
3 20201
4 202071
5 201870
6 2018305
7 2017146
8 201768
9 20162
10 2015163
11 201522
12
Quantitative Structure Activity Relationship Analysis of N Phenazine -1-carboxamides Analogs as Anti mycobacterial Agents
20141
13 20121
14 201114

About Ashvin R. Jaiswal

Ashvin R. Jaiswal is a scholar working on Research and Theory, Immunology and Oncology, having authored 14 papers that have together received 914 indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (7 papers), Immune cells in cancer (4 papers), Immune Cell Function and Interaction (4 papers), Immunotherapy and Immune Responses (3 papers), CAR-T cell therapy research (2 papers), Cancer therapeutics and mechanisms (1 paper), interferon and immune responses (1 paper) and Inflammation biomarkers and pathways (1 paper). The work is most often cited by research in Immunology (482 citations), Oncology (387 citations) and Cancer Research (195 citations). Ashvin R. Jaiswal has collaborated with scholars based in United States, Israel and Brazil. Frequent co-authors include Michael A. Curran, Casey R. Ager, Todd Bartkowiak, Courtney Nicholas, Matthew J. Reilley, Shiva Adireddy, Arthur Liu, Benjamin Lee, Sree Harsha Mandava and Douglas B. Chrisey. Their work appears in journals such as Journal of Clinical Investigation, Nature Communications and The Journal of Immunology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026